6.93 USD
+0.07 (+1.02%)
6.93 USD
0 (0%)
MDXG gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. While MDXG has a great health rating, its profitability is only average at the moment. A decent growth rate in combination with a cheap valuation! Better keep an eye on MDXG. These ratings would make MDXG suitable for value investing!
1. Profitability
1.1 Basic Checks
In the past year MDXG was profitable.
MDXG had a positive operating cash flow in the past year.
In multiple years MDXG reported negative net income over the last 5 years.
In multiple years MDXG reported negative operating cash flow during the last 5 years.
1.2 Ratios
MDXG has a Return On Assets of 12.80%. This is amongst the best in the industry. MDXG outperforms 94.57% of its industry peers.
MDXG has a better Return On Equity (17.09%) than 95.13% of its industry peers.
MDXG has a better Return On Invested Capital (15.15%) than 95.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROIC | 15.15% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MDXG has a better Profit Margin (10.38%) than 92.13% of its industry peers.
With an excellent Operating Margin value of 13.73%, MDXG belongs to the best of the industry, outperforming 93.07% of the companies in the same industry.
In the last couple of years the Operating Margin of MDXG has remained more or less at the same level.
The Gross Margin of MDXG (81.99%) is better than 85.39% of its industry peers.
MDXG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
MDXG has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, MDXG has more shares outstanding
MDXG has more shares outstanding than it did 5 years ago.
MDXG has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 9.89 indicates that MDXG is not in any danger for bankruptcy at the moment.
MDXG has a better Altman-Z score (9.89) than 81.84% of its industry peers.
MDXG has a debt to FCF ratio of 0.27. This is a very positive value and a sign of high solvency as it would only need 0.27 years to pay back of all of its debts.
MDXG's Debt to FCF ratio of 0.27 is amongst the best of the industry. MDXG outperforms 95.13% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that MDXG is not too dependend on debt financing.
MDXG has a Debt to Equity ratio of 0.07. This is in the lower half of the industry: MDXG underperforms 61.61% of its industry peers.
Even though the debt/equity ratio score it not favorable for MDXG, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Altman-Z | 9.89 |
ROIC/WACC1.74
WACC8.69%
2.3 Liquidity
A Current Ratio of 4.41 indicates that MDXG has no problem at all paying its short term obligations.
The Current ratio of MDXG (4.41) is comparable to the rest of the industry.
A Quick Ratio of 3.95 indicates that MDXG has no problem at all paying its short term obligations.
MDXG has a Quick ratio of 3.95. This is comparable to the rest of the industry: MDXG outperforms 49.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 |
3. Growth
3.1 Past
MDXG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -35.71%.
Looking at the last year, MDXG shows a quite strong growth in Revenue. The Revenue has grown by 14.77% in the last year.
The Revenue has been growing slightly by 3.11% on average over the past years.
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
3.2 Future
The Earnings Per Share is expected to grow by 17.40% on average over the next years. This is quite good.
Based on estimates for the next years, MDXG will show a quite strong growth in Revenue. The Revenue will grow by 14.49% on average per year.
EPS Next Y49.48%
EPS Next 2Y8.55%
EPS Next 3Y17.4%
EPS Next 5YN/A
Revenue Next Year17.88%
Revenue Next 2Y9.84%
Revenue Next 3Y10.43%
Revenue Next 5Y14.49%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 19.25 indicates a rather expensive valuation of MDXG.
94.19% of the companies in the same industry are more expensive than MDXG, based on the Price/Earnings ratio.
MDXG's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.46.
A Price/Forward Earnings ratio of 20.28 indicates a rather expensive valuation of MDXG.
Based on the Price/Forward Earnings ratio, MDXG is valued cheaper than 94.19% of the companies in the same industry.
MDXG is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 36.10, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.25 | ||
| Fwd PE | 20.28 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MDXG is valued cheaper than 95.51% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, MDXG is valued cheaper than 96.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.36 | ||
| EV/EBITDA | 12.99 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MDXG may justify a higher PE ratio.
MDXG's earnings are expected to grow with 17.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.39
PEG (5Y)N/A
EPS Next 2Y8.55%
EPS Next 3Y17.4%
5. Dividend
5.1 Amount
No dividends for MDXG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
6.93
+0.07 (+1.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners71.57%
Inst Owner Change-0.71%
Ins Owners1.83%
Ins Owner Change0.17%
Market Cap1.03B
Revenue(TTM)393.44M
Net Income(TTM)40.83M
Analysts81.82
Price Target12.44 (79.51%)
Short Float %3.22%
Short Ratio5.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.82%
Min EPS beat(2)81.55%
Max EPS beat(2)110.08%
EPS beat(4)3
Avg EPS beat(4)41.67%
Min EPS beat(4)-31.92%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)78.91%
EPS beat(12)11
Avg EPS beat(12)70.05%
EPS beat(16)12
Avg EPS beat(16)53.63%
Revenue beat(2)2
Avg Revenue beat(2)12.56%
Min Revenue beat(2)6.68%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)6.82%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)3.48%
Revenue beat(12)9
Avg Revenue beat(12)3.71%
Revenue beat(16)12
Avg Revenue beat(16)3.45%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)21.15%
EPS NQ rev (3m)21.15%
EPS NY rev (1m)30.77%
EPS NY rev (3m)30.77%
Revenue NQ rev (1m)2.37%
Revenue NQ rev (3m)2.37%
Revenue NY rev (1m)5.61%
Revenue NY rev (3m)5.61%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.25 | ||
| Fwd PE | 20.28 | ||
| P/S | 2.61 | ||
| P/FCF | 15.36 | ||
| P/OCF | 15.13 | ||
| P/B | 4.3 | ||
| P/tB | 4.93 | ||
| EV/EBITDA | 12.99 |
EPS(TTM)0.36
EY5.19%
EPS(NY)0.34
Fwd EY4.93%
FCF(TTM)0.45
FCFY6.51%
OCF(TTM)0.46
OCFY6.61%
SpS2.66
BVpS1.61
TBVpS1.41
PEG (NY)0.39
PEG (5Y)N/A
Graham Number3.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROCE | 20.67% | ||
| ROIC | 15.15% | ||
| ROICexc | 33.2% | ||
| ROICexgc | 44.66% | ||
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% | ||
| FCFM | 16.98% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score6
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 6.96% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 36.69 | ||
| Cash Conversion | 98.8% | ||
| Profit Quality | 163.64% | ||
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 | ||
| Altman-Z | 9.89 |
F-Score6
WACC8.69%
ROIC/WACC1.74
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y49.48%
EPS Next 2Y8.55%
EPS Next 3Y17.4%
EPS Next 5YN/A
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
Revenue Next Year17.88%
Revenue Next 2Y9.84%
Revenue Next 3Y10.43%
Revenue Next 5Y14.49%
EBIT growth 1Y-14.78%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year35.54%
EBIT Next 3Y15.54%
EBIT Next 5Y22.59%
FCF growth 1Y787.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y522.28%
OCF growth 3YN/A
OCF growth 5YN/A
MIMEDX GROUP INC / MDXG FAQ
Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to MDXG.
What is the valuation status of MIMEDX GROUP INC (MDXG) stock?
ChartMill assigns a valuation rating of 7 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Undervalued.
What is the profitability of MDXG stock?
MIMEDX GROUP INC (MDXG) has a profitability rating of 6 / 10.
What is the valuation of MIMEDX GROUP INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for MIMEDX GROUP INC (MDXG) is 19.25 and the Price/Book (PB) ratio is 4.3.
What is the financial health of MIMEDX GROUP INC (MDXG) stock?
The financial health rating of MIMEDX GROUP INC (MDXG) is 7 / 10.